Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society

Takashi Hojo, Norikazu Masuda, Takayuki Iwamoto, Naoki Niikura, Keisei Anan, Kenjiro Aogi, Tatsuya Ohnishi, Chisako Yamauchi, Masayuki Yoshida, Takayuki Kinoshita, Hideji Masuoka, Yasuaki Sagara, Takashi Sakatani, Yasuyuki Kojima, Hitoshi Tsuda, Hiraku Kumamaru, Hiroaki Miyata, Seigo Nakamura

Research output: Contribution to journalArticle

Abstract

Background: Adding taxane to an anthracycline-based regimen improves survival in node-positive breast cancer patients, as shown by clinical trials and meta-analyses. However, no studies have analyzed the number of metastatic lymph nodes in patients with estrogen receptor (ER)-positive cancer. This study investigated whether adding a taxane to an anthracycline-based regimen improved prognosis in node-positive, ER-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients in a real-world setting. Methods: Using Japanese Breast Cancer Society registry data, we compared disease-free survival (DFS) of patients with ER-positive, HER2-negative breast cancer, excluding those receiving neoadjuvant chemotherapy, between those who received an anthracycline-based regimen followed by a taxane-based regimen (A + T) and those who received only an anthracycline-based regimen (A w/o T), stratified by lymph node status. A Cox proportional hazards model was used to evaluate DFS in both groups. Results: There were 4566 eligible patients with ER-positive, HER2-negative breast cancer. During the median follow-up period of 60 months, there were 481 recurrences and 149 deaths. There was no significant difference in DFS between the A + T and A w/o T groups among patients with 1–3 positive nodes, while there was a significant difference among patients with ≥ 4 positive nodes. Conclusions: In patients with ER-positive, HER2-negative breast cancer, adding taxane to an anthracycline regimen did not improve DFS in patients with metastasis in 1–3 lymph nodes. We considered that the group without the addition of taxane might be present in patients with ER-positive, HER2-negative lymph node metastases.

Original languageEnglish
JournalBreast Cancer
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Adjuvant Chemotherapy
Estrogen Receptors
Registries
Breast Neoplasms
Anthracyclines
Disease-Free Survival
Lymph Nodes
taxane
Neoplasm Metastasis
Proportional Hazards Models
Meta-Analysis
human ERBB2 protein
Clinical Trials
Recurrence
Drug Therapy
Survival

Keywords

  • Adjuvant chemotherapy regimen
  • Anthracycline
  • Estrogen receptor positive
  • Node-positive breast cancer
  • Taxane

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society. / Hojo, Takashi; Masuda, Norikazu; Iwamoto, Takayuki; Niikura, Naoki; Anan, Keisei; Aogi, Kenjiro; Ohnishi, Tatsuya; Yamauchi, Chisako; Yoshida, Masayuki; Kinoshita, Takayuki; Masuoka, Hideji; Sagara, Yasuaki; Sakatani, Takashi; Kojima, Yasuyuki; Tsuda, Hitoshi; Kumamaru, Hiraku; Miyata, Hiroaki; Nakamura, Seigo.

In: Breast Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Hojo, T, Masuda, N, Iwamoto, T, Niikura, N, Anan, K, Aogi, K, Ohnishi, T, Yamauchi, C, Yoshida, M, Kinoshita, T, Masuoka, H, Sagara, Y, Sakatani, T, Kojima, Y, Tsuda, H, Kumamaru, H, Miyata, H & Nakamura, S 2019, 'Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society', Breast Cancer. https://doi.org/10.1007/s12282-019-00997-w
Hojo, Takashi ; Masuda, Norikazu ; Iwamoto, Takayuki ; Niikura, Naoki ; Anan, Keisei ; Aogi, Kenjiro ; Ohnishi, Tatsuya ; Yamauchi, Chisako ; Yoshida, Masayuki ; Kinoshita, Takayuki ; Masuoka, Hideji ; Sagara, Yasuaki ; Sakatani, Takashi ; Kojima, Yasuyuki ; Tsuda, Hitoshi ; Kumamaru, Hiraku ; Miyata, Hiroaki ; Nakamura, Seigo. / Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society. In: Breast Cancer. 2019.
@article{97f54793dea347c6ab7f6439f4ce2c7c,
title = "Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society",
abstract = "Background: Adding taxane to an anthracycline-based regimen improves survival in node-positive breast cancer patients, as shown by clinical trials and meta-analyses. However, no studies have analyzed the number of metastatic lymph nodes in patients with estrogen receptor (ER)-positive cancer. This study investigated whether adding a taxane to an anthracycline-based regimen improved prognosis in node-positive, ER-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients in a real-world setting. Methods: Using Japanese Breast Cancer Society registry data, we compared disease-free survival (DFS) of patients with ER-positive, HER2-negative breast cancer, excluding those receiving neoadjuvant chemotherapy, between those who received an anthracycline-based regimen followed by a taxane-based regimen (A + T) and those who received only an anthracycline-based regimen (A w/o T), stratified by lymph node status. A Cox proportional hazards model was used to evaluate DFS in both groups. Results: There were 4566 eligible patients with ER-positive, HER2-negative breast cancer. During the median follow-up period of 60 months, there were 481 recurrences and 149 deaths. There was no significant difference in DFS between the A + T and A w/o T groups among patients with 1–3 positive nodes, while there was a significant difference among patients with ≥ 4 positive nodes. Conclusions: In patients with ER-positive, HER2-negative breast cancer, adding taxane to an anthracycline regimen did not improve DFS in patients with metastasis in 1–3 lymph nodes. We considered that the group without the addition of taxane might be present in patients with ER-positive, HER2-negative lymph node metastases.",
keywords = "Adjuvant chemotherapy regimen, Anthracycline, Estrogen receptor positive, Node-positive breast cancer, Taxane",
author = "Takashi Hojo and Norikazu Masuda and Takayuki Iwamoto and Naoki Niikura and Keisei Anan and Kenjiro Aogi and Tatsuya Ohnishi and Chisako Yamauchi and Masayuki Yoshida and Takayuki Kinoshita and Hideji Masuoka and Yasuaki Sagara and Takashi Sakatani and Yasuyuki Kojima and Hitoshi Tsuda and Hiraku Kumamaru and Hiroaki Miyata and Seigo Nakamura",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12282-019-00997-w",
language = "English",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society

AU - Hojo, Takashi

AU - Masuda, Norikazu

AU - Iwamoto, Takayuki

AU - Niikura, Naoki

AU - Anan, Keisei

AU - Aogi, Kenjiro

AU - Ohnishi, Tatsuya

AU - Yamauchi, Chisako

AU - Yoshida, Masayuki

AU - Kinoshita, Takayuki

AU - Masuoka, Hideji

AU - Sagara, Yasuaki

AU - Sakatani, Takashi

AU - Kojima, Yasuyuki

AU - Tsuda, Hitoshi

AU - Kumamaru, Hiraku

AU - Miyata, Hiroaki

AU - Nakamura, Seigo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Adding taxane to an anthracycline-based regimen improves survival in node-positive breast cancer patients, as shown by clinical trials and meta-analyses. However, no studies have analyzed the number of metastatic lymph nodes in patients with estrogen receptor (ER)-positive cancer. This study investigated whether adding a taxane to an anthracycline-based regimen improved prognosis in node-positive, ER-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients in a real-world setting. Methods: Using Japanese Breast Cancer Society registry data, we compared disease-free survival (DFS) of patients with ER-positive, HER2-negative breast cancer, excluding those receiving neoadjuvant chemotherapy, between those who received an anthracycline-based regimen followed by a taxane-based regimen (A + T) and those who received only an anthracycline-based regimen (A w/o T), stratified by lymph node status. A Cox proportional hazards model was used to evaluate DFS in both groups. Results: There were 4566 eligible patients with ER-positive, HER2-negative breast cancer. During the median follow-up period of 60 months, there were 481 recurrences and 149 deaths. There was no significant difference in DFS between the A + T and A w/o T groups among patients with 1–3 positive nodes, while there was a significant difference among patients with ≥ 4 positive nodes. Conclusions: In patients with ER-positive, HER2-negative breast cancer, adding taxane to an anthracycline regimen did not improve DFS in patients with metastasis in 1–3 lymph nodes. We considered that the group without the addition of taxane might be present in patients with ER-positive, HER2-negative lymph node metastases.

AB - Background: Adding taxane to an anthracycline-based regimen improves survival in node-positive breast cancer patients, as shown by clinical trials and meta-analyses. However, no studies have analyzed the number of metastatic lymph nodes in patients with estrogen receptor (ER)-positive cancer. This study investigated whether adding a taxane to an anthracycline-based regimen improved prognosis in node-positive, ER-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients in a real-world setting. Methods: Using Japanese Breast Cancer Society registry data, we compared disease-free survival (DFS) of patients with ER-positive, HER2-negative breast cancer, excluding those receiving neoadjuvant chemotherapy, between those who received an anthracycline-based regimen followed by a taxane-based regimen (A + T) and those who received only an anthracycline-based regimen (A w/o T), stratified by lymph node status. A Cox proportional hazards model was used to evaluate DFS in both groups. Results: There were 4566 eligible patients with ER-positive, HER2-negative breast cancer. During the median follow-up period of 60 months, there were 481 recurrences and 149 deaths. There was no significant difference in DFS between the A + T and A w/o T groups among patients with 1–3 positive nodes, while there was a significant difference among patients with ≥ 4 positive nodes. Conclusions: In patients with ER-positive, HER2-negative breast cancer, adding taxane to an anthracycline regimen did not improve DFS in patients with metastasis in 1–3 lymph nodes. We considered that the group without the addition of taxane might be present in patients with ER-positive, HER2-negative lymph node metastases.

KW - Adjuvant chemotherapy regimen

KW - Anthracycline

KW - Estrogen receptor positive

KW - Node-positive breast cancer

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=85069459949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069459949&partnerID=8YFLogxK

U2 - 10.1007/s12282-019-00997-w

DO - 10.1007/s12282-019-00997-w

M3 - Article

AN - SCOPUS:85069459949

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

ER -